San Diego, CA 7/6/2009 8:24:23 PM
BioPharma Stocks to Watch - WWBP, AVRO, CFAWF, May Be Ready to Run
China Fortune Acquisition Warrants (CFAWF), Worldwide Bio and Pharmaceutical Inc., (WWBP), and Averion International Corp. (AVRO)
China Fortune Acquisition Warrants (CFAWF), Worldwide Bio and Pharmaceutical Inc., (WWBP), and Averion International Corp. (AVRO) were among Thursday's biggest market winners, setting each of them up as a breakout candidate for this week. A review and analysis of each chart and company has been provided at the Small Cap Network.
Investors can review the entire article and opinion on the China Fortune Acquisition Warrants, Worldwide Bio and Pharmaceutical Inc., and Averion International Corp. - along with other trading commentary and market trend analysis - by visiting: www.smallcapnetwork.com/t/.
About Averion International Corp.
Averion International Corp. (AVRO) is a leading international CRO with proven expertise in supporting global clinical trials for pharmaceutical, biotechnology and medical device companies. The Company has a therapeutic focus in oncology, cardiovascular diseases and medical devices. Averion’s core competencies are in FDA and product registration support, site selection, project management, medical and site monitoring, data management, biometrics, pharmacovigilance, medical writing, and full clinical trial management services throughout the clinical trials lifecycle. The Company has supported FDA approvals for products in many therapeutic areas including oncology, cardiovascular diseases and medical devices.
About Worldwide Biotech & Pharmaceutical Company
Worldwide Biotech & Pharmaceutical Company (WWBP), a biopharmaceutical company, together with its subsidiaries, specializes in the development and marketing of viruses/viral vectors, bio-medicines, external diagnostic reagents, prophylactic vaccines for humans, and oral dosage forms of traditional Chinese medicine. It also engages in developing a hepatitis C vaccine. The company’s products include hepatitis C virus (HCV) produced in-vitro; Elisa kits for HCV antibody detection; anti-HCV medicines; and HCV human vaccines. It also engages in the research, development, and manufacture of over-the-counter traditional Chinese medicines, synthetic medicines, and functional foods; and distribution of medical devices and other medical products. In addition, the company provides an anti HCV drug-screening assay based on its in vitro cell culture system for the primary screening of anti-HCV medicines.
About China Fortune Acquisition Corp.
China Fortune Acquisition Corp. (CFAQF) was formed with the purpose of acquiring, through a stock exchange, asset acquisition or other similar business combination, an operating business, or control of such operating business through contractual arrangements, that has its principal operations located in the People’s Republic of China.
About Us
The Small Cap Network is one of the web's leading small cap stock trading communities. Though large caps tend to receive the majority of media attention, small and micro cap stocks as well as penny stocks can often offer the most potential for investment gains. The Small Cap Network web site and free newsletter offer in-depth fundamental research and technical trading recommendations on select companies within the global equity markets, including small cap stocks, micro cap stocks, bulletin board stocks, and actively traded penny stocks.
Investors and traders are invited to subscribe to the free Small Cap Network Newsletter, which offers other trading ideas and insights at: www.smallcapnetwork.com/t/.
Forward-Looking Statement: This press release may include or imply "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
SmallCapNetwork.com is not a registered investment adviser or broker/dealer. SmallCapNetwork.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for many of their securities, investing in such securities is highly speculative and carries a high degree of risk.
Contact Information:
Small Cap Network
4653 Carmel Mtn. Rd
Suite 308 #402
San Diego, CA 92130
Email: editor@smallcapnetwork.com
Source: Small Cap Network
